Cystic fibrosis - mannitol: final appraisal determinaton
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on mannitol dry powder for inhalation for the treatment of cystic fibrosis and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 9 November 2012.
Cystic fibrosis - mannitol: final appraisal determinaton
Cystic fibrosis - mannitol: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
Cystic fibrosis - mannitol: consultee and commentator comments on the ACD
Cystic fibrosis - mannitol: expert comments on the ACD
Cystic fibrosis - mannitol: comments on the ACD received from the public through the NICE website
Cystic fibrosis - mannitol: addendum to Evidence Review Group's Report following Pharmaxis' new evidence submission of 3rd July 2012
This page was last updated: 24 October 2012